Buscar en
Hipertensión y Riesgo Vascular
Toda la web
Inicio Hipertensión y Riesgo Vascular A comparison effects of l-citrulline and l-arginine against cyclosporine-induced...
Journal Information
Vol. 38. Issue 4.
Pages 170-177 (October - December 2021)
Share
Share
Download PDF
More article options
Visits
139
Vol. 38. Issue 4.
Pages 170-177 (October - December 2021)
Original article
A comparison effects of l-citrulline and l-arginine against cyclosporine-induced blood pressure and biochemical changes in the rats
Comparación de los efectos de L-citrulina y L-arginina frente a la presión arterial inducida por ciclosporina y los cambios bioquímicos en ratas
Visits
139
S.R. Hashemia, H.A. Araba,
Corresponding author
harab@ut.ac.ir

Corresponding author.
, B. Seifib, S. Muhammadnejadc
a Department of Comparative Biosciences, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran
b Department of Physiology, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran
c Research Center for Molecular and Cellular Imaging, Tehran University of Medical Sciences, Tehran, Iran
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (2)
Tables (1)
Table 1. The values of biochemical parameters measured in the blood of rats received different treatment of cyclosporine A (CsA), citruline (CIT), arginine (ARG), cyclosporine+citruline (CsA+CIT) and cyclosporine+arginine (CsA+ARG). All data are expressed as mean±SD obtained from at least 6 rats in each group#,$.
Abstract
Objective

The use of cyclosporine A (CsA) is associated with different adverse effects including hypertension and nephrotoxicity. The present study aimed to compare the inhibitory effects of l-arginine & l-citrulline on CsA-induced blood pressure and biochemical changes in the serum of rats.

Methods

Thirty-six rats were divided into 6 groups received daily: (1) 1ml distilled water, (2) 200mg/kg l-citrulline IP, (3) 25mg/kg CsA SC, (4) CsA+l-citrulline with the same dose of the former groups, (5) 200mg/kg l-arginine IP and (6) l-arginie+CsA with the same doses of group 4 for 7 days.

Results

The changes in the blood pressure, heart rate, creatinine, BUN, glucose and C-reactive protein (CRP) of the serum were determined in the treated animals. Significant (p<0.001) increase was shown in the blood pressure and heart rate of CsA treated rats compared to the control group. There were also a significant (p<0.05) increase in the creatinine, BUN and glucose, but a decrease in the CRP value in the CsA-treated group. However, l-citrulline significantly (p<0.001) inhibited the changes in the blood pressure and heart rate in CsA-treated as well as it was able to reduce blood pressure in non-treated group significantly (p<0.01). l-citrulline also inhibited the increased levels of BUN and creatinine induced by CsA, while, l-arginine was able to prevent the increased blood pressure and creatinine occurs after administration of CsA.

Conclusions

These findings suggest that the l-citrulline is more efficient than l-arginine against the adverse effects induced by cyclosporine.

Keywords:
Cyclosporine
Hypertension
l-Citrulline
l-Arginine
Systolic blood pressure
Resumen
Objetivo

El uso de ciclosporina A (CsA) está asociado a diferentes efectos adversos que incluyen hipertensión y nefrotoxicidad. El objetivo del presente estudio es comparar los efectos inhibitorios de L-arginina y L-citrulina en la presión arterial inducida por CsA, y los cambios bioquímicos a nivel sérico en ratas.

Métodos

Se dividieron 36 ratas en 6 grupos, que recibieron diariamente: 1) 1ml de agua destilada, 2) 200mg/kg de L-citrulina IP, 3) 25mg/kg de CsA SC, 4) la misma dosificación que los grupos anteriores de CsA+L-citrulina, 5) 200mg/kg de L-arginina IP y 6) la misma dosificación que el grupo 4 durante 7 días de L-arginina+CsA.

Resultados

Se determinaron los cambios de presión arterial, frecuencia cardiaca, creatinina, BUN, glucosa y proteína C reactiva (PCR) a nivel sérico, en los animales tratados. Se observó un incremento significativo (p<0,001) de presión arterial y frecuencia cardiaca en las ratas tratadas con CsA en comparación con el grupo control. También se produjo un incremento significativo (p<0,05) de los niveles de creatinina, BUN y glucosa, y una reducción del valor de PCR en el grupo tratado con CsA. Sin embargo, L-citrulina inhibió significativamente (p<0,001) los cambios de presión arterial y frecuencia cardiaca en las ratas tratadas con CsA, y también pudo reducir la presión arterial de manera considerable en el grupo no tratado (p<0,01). L-citrulina inhibió también los niveles incrementados de BUN y creatinina inducidos por CsA, y L-arginina fue capaz de impedir la incidencia del incremento de presión arterial y creatinina tras la administración de CsA.

Conclusiones

Estos hallazgos sugieren que L-citrulina es más efectiva que L-arginina frente a los efectos adversos inducidos por ciclosporina.

Palabras clave:
Ciclosporina
Hipertensión
L-citrulina
L-arginina
Presión arterial sistólica

Article

These are the options to access the full texts of the publication Hipertensión y Riesgo Vascular
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Hipertensión y Riesgo Vascular

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
10.1016/j.hipert.2023.11.006
No mostrar más